New Two-Pronged attack on Tough-to-Treat blood cancer
NCT ID NCT06947083
Summary
This study is testing whether adding a maintenance drug called elranatamab after CAR-T cell therapy can help keep myeloma from returning in high-risk patients. It will enroll 39 adults with relapsed myeloma who have already received CAR-T cell treatment but have features that make their cancer more likely to come back. The main goal is to see if this combination approach helps patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.